IC
ODT

Ikarian Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Ikarian Capital’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,340,631
Closed -$1.81M – 221
2021
Q4 		$1.81M Sell
1,340,631
-500,000
-27% -$1.18M 0.27% 71
2021
Q3 		$5.36M Sell
1,840,631
-145,781
-7% -$485K 0.38% 62
2021
Q2 		$6.93M Buy
1,986,412
+650,000
+49% +$2.23M 0.56% 49
2021
Q1 		$4.57M Buy
+1,336,412
New +$25.3M 0.15% 126

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Ikarian Capital's ODT Position: Q1 2022 in Review

Ikarian Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 1,340,631 shares — an estimated $1.81M sold.

Ikarian Capital first reported a position in ODT in Q1 2021 and held it in 4 quarters. The position peaked at $6.93M in Q2 2021. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Ikarian Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Ikarian Capital sold 1,340,631 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.81M.
  • Ikarian Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Ikarian Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $6.93M in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.